This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2021 Sep;20(9):663-664.

doi: 10.1038/d41573-021-00111-w.

The prostate cancer drug market

Carolina do Pazo, Rachel M Webster

PMID: 34145436
DOI: 10.1038/d41573-021-00111-w

The prostate cancer drug market

Carolina do Pazo et al. Nat Rev Drug Discov. 2021 Sep.

. 2021 Sep;20(9):663-664.

doi: 10.1038/d41573-021-00111-w.

Authors

Carolina do Pazo, Rachel M Webster

PMID: 34145436
DOI: 10.1038/d41573-021-00111-w

No abstract available

PubMed Disclaimer

Similar articles

Moving upstream in anticancer drug development.
Hait WN, Lebowitz PF. Hait WN, et al. Nat Rev Drug Discov. 2019 Mar;18(3):159-160. doi: 10.1038/d41573-018-00006-3. Nat Rev Drug Discov. 2019. PMID: 30858576 No abstract available.
Weekly chemotherapeutic regimen in metastatic prostate cancer.
Burk K. Burk K. Prog Clin Biol Res. 1990;350:187-200. Prog Clin Biol Res. 1990. PMID: 2201043 Review.
Personalizing prostate cancer therapy: the way forward.
Cetnar JP, Beer TM. Cetnar JP, et al. Drug Discov Today. 2014 Sep;19(9):1483-7. doi: 10.1016/j.drudis.2014.07.006. Epub 2014 Jul 18. Drug Discov Today. 2014. PMID: 25046532 Review.
PARP inhibitors and stratified treatment of prostate cancer.
Lavery A, Gilson C, Chowdhury S. Lavery A, et al. Expert Rev Anticancer Ther. 2016 Dec;16(12):1213-1215. doi: 10.1080/14737140.2016.1243474. Epub 2016 Oct 17. Expert Rev Anticancer Ther. 2016. PMID: 27686597 No abstract available.
Adjuvant chemotherapy for T3 prostate cancer: not ready for prime time.
Carducci MA. Carducci MA. Urology. 2000 Feb;55(2):157-60. doi: 10.1016/s0090-4295(99)00366-0. Urology. 2000. PMID: 10688070 No abstract available.

See all similar articles

Cited by

From Concept to Regulatory Drug Approval: Lessons for Theranostics.
Perera M, Morris MJ. Perera M, et al. J Nucl Med. 2022 Dec;63(12):1793-1801. doi: 10.2967/jnumed.121.263301. J Nucl Med. 2022. PMID: 36456108 Free PMC article. Review.
AAT resistance-related AC007405.2 and AL354989.1 as novel diagnostic and prognostic markers in prostate cancer.
Deng Y, Zhang C, Yu H, Chen G, Peng X, Li Y, Feng Z, Shi W, Bai X, Gou X, Liu N. Deng Y, et al. Aging (Albany NY). 2024 Apr 19;16(8):7249-7266. doi: 10.18632/aging.205754. Epub 2024 Apr 19. Aging (Albany NY). 2024. PMID: 38643469 Free PMC article.
Oncological Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide with versus without Confirmatory Bone Scan.
Jeong CW, Han JH, Kwon DD, Joung JY, Kim CS, Ahn H, Hong JH, Kim TH, Chung BH, Jeon SS, Kang M, Hong SK, Jung TY, Park SW, Yun SJ, Lee JY, Lee SH, Kang SH, Kwak C. Jeong CW, et al. Cancer Res Treat. 2024 Apr;56(2):634-641. doi: 10.4143/crt.2023.848. Epub 2023 Dec 5. Cancer Res Treat. 2024. PMID: 38062708 Free PMC article.
Investigation of the GnRH antagonist degarelix isomerization in biological matrices.
Ferrazzano L, Tolomelli A, Guryanov I, Macis M, Abel U, Ricci A, Cabri W. Ferrazzano L, et al. Pharmacol Res Perspect. 2023 Aug;11(4):e01117. doi: 10.1002/prp2.1117. Pharmacol Res Perspect. 2023. PMID: 37455491 Free PMC article.
A Mini-Review of Flavone Isomers Apigenin and Genistein in Prostate Cancer Treatment.
Ji X, Liu K, Li Q, Shen Q, Han F, Ye Q, Zheng C. Ji X, et al. Front Pharmacol. 2022 Mar 11;13:851589. doi: 10.3389/fphar.2022.851589. eCollection 2022. Front Pharmacol. 2022. PMID: 35359832 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Medical
- MedlinePlus Health Information